The current study findings have negated the previous assumption that HT use contributes to a reduction in DES among postmenopausal women. Instead, prolonged HT use seems to increase the risk of DES.

Over the decades, female sexual dysfunction (FSD) has grown to be an increasingly potential problem that complicates the quality of life among women. In the current review, FSD refers to recurrent and persistent problems with sexual orgasm, desire, or response. One of the most common subtypes of FSD that has evoked increased research interest in the scientific community is hyposexuality. Today, there is a consensus that hyposexuality is a multifactorial condition that manifests with reduced sexual desire resulting in significant interpersonal distress. The objective of the current review was to examine how hormonal profile triggers propagate hypoactive sexual desire disorder (HSDD), and to highlight effective treatment interventions that can be used to manage the condition. The current review describes HSDD as a sexual dysfunction characterized by the absence or lack of sexual desire and fantasies for sexual activities. The review argues that even if the role of sexual hormones is essential in modulating HSDD through therapeutic interventions, an effective comprehension of the biologic mechanisms underlying HSDD is necessary. There is a consensus in the literature that HSDD still poses significant challenges due to the lack of properly formulated treatment regimens and absence of clear clinical guidelines. That is, a better intervention consisting of both psycho-relational and biologic aspects is compulsory if tailored management and accurate diagnosis of HSDD in clinical practice are to be realised. The review concludes that, to date, a reliable clinical intervention to manage hyposexuality is still absent and more interventions, in terms of safety and efficacy, are required. Thus, additional investigation is required to document precise hormonal or non-hormonal pharmacotherapeutic agents for individualised care among patients with HSDD.

Background: Previous research has documented that sexual abstinence can improve sperm quality. Sexologists have reported that sperms stored in a latex condom decrease at a rate of 60% per minute. Objective: The objective of the current review is to explore the relationship between sexual abstinence duration and other factors that affect standard and substandard semen production. Design: A scientific review of published literature. Main Outcome Measure: Specific focus is to discuss how sexual abstinence behaviours relate to the production, quality and efficiency of sperms and semen in relation to the different characteristics such as duration of abstinence, age, and psychological behaviours. The study will also seek to verify if there is a link between sexual abstinence and semen production or what triggers semen production in men. Results: From the reviewed literature, data analysis on oligozoospermic samples indicated a peak motility of 30% after 1 day of abstinence. After 2 days of abstinence, the recorded average percentage of the normal sperm morphologies among the moderate and mild oligozoospermic samples ranged from 7% to 8.5%. The increase of the normal sperm morphology was statistically significant (P < 0.003) and sperm motility (P < 0.001) that were in line with the average percentage production of 7.5% and 31.9%, respectively. The significant sperm production was recorded between day 3 and day 8 of abstinence. Conclusion:The data obtained supports the literature on abstinence in facilitating male infertility treatment. Thus, the data argues that so as to present the best semen samples for fertility treatment, men should collect semen sample after 3-8 days of abstinence as recommended by the World Health Organization (WHO). Patients that present normal sperms give sperm donations for cryopreservation ought to be informed not to exceed the 10-day abstinence duration as the quality of the sperms is compromised.